Table 1.
Characteristics, sources of bacteremia and illness severity of patients with bacteremia
| SLB (n = 22) | SEB (n = 110) | SAB (n = 110) | P value among three groups |
P value SLB—SEB |
P value SLB—SAB |
|
|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||||
| Age (years), median (IQR) | 70 (63–80) | 64 (50–73) | 68 (47–76) | 0.09 | ||
| Male | 11 (50) | 68 (62) | 59 (54) | 0.37 | ||
| Healthcare setting | < 0.01 | < 0.01 | 0.28 | |||
| Community-acquired | 5 (23) | 2 (2) | 16 (15) | |||
| Health care-associated | 7 (32) | 7 (6) | 24 (22) | |||
| Hospital-acquired | 10 (45) | 101 (92) | 70 (64) | |||
| Methicillin resistance | 5 (23) | 91 (83) | 35 (32) | < 0.01 | < 0.01 | 0.40 |
| Comorbidities | ||||||
| Diabetes | 7 (32) | 22 (20) | 20 (18) | 0.23 | ||
| Hemodialysis | 5 (23) | 8 (7) | 12 (11) | 0.09 | ||
| Malignancy | 13 (59) | 66 (60) | 50 (45) | 0.08 | ||
| Solid organ cancer | 9 (41) | 33 (30) | 42 (38) | 0.36 | ||
| Hematological cancer | 4 (18) | 37 (34) | 9 (8) | < 0.01 | 0.15 | 0.15 |
| Liver cirrhosis | 0 | 6 (5) | 10 (9) | 0.24 | ||
| Immunosuppressants | 7 (32) | 53 (48) | 31 (28) | < 0.01 | 0.16 | 0.73 |
| Chemotherapy | 6 (27) | 45 (41) | 22 (20) | < 0.01 | 0.23 | 0.45 |
| Charlson index, median (IQR) | 3 (2–6) | 2 (2–4) | 3 (2–5) | 0.29 | ||
| Intravascular catheterization | 10 (45) | 101 (92) | 68 (62) | < 0.01 | < 0.01 | 0.15 |
| Implantable Devices | 5 (23) | 16 (15) | 28 (25) | 0.13 | ||
| Intra vascular | 2 (9) | 6 (5) | 11 (10) | |||
| Implantable cardiac | 2 (9) | 1 1) | 6 (5) | |||
| Orthopedic device | 1 (5) | 8 (7) | 13 (12) | |||
| Source of bacteremia | ||||||
| Intravascular catheter-related | 5 (23) | 50 (45) | 29 (26) | < 0.01 | 0.048 | 0.72 |
| Skin and soft tissue | 5 (23) | 0 | 14 (13) | < 0.01 | < 0.01 | 0.22 |
| Endovascular | 5 (23) | 5 (5) | 13 (12) | 0.02 | < 0.01 | 0.17 |
| Infective endocarditis | 3 (14) | 2 (2) | 6 (5) | 0.04 | < 0.01 | 0.16 |
| Vascular graft infection | 0 | 1 (1) | 0 | 0.55 | ||
| Suppurative thrombophlebitis | 2 (9) | 2 (2) | 7 (6) | 0.15 | ||
| Bone and joint | 0 | 2 (2) | 5 (5) | 0.34 | ||
| Lung | 1 (5) | 0 | 6 (5) | 0.01 | 0.06 | 0.9 |
| Intra-abdominal | 1 (5) | 0 | 5 (5) | 0.08 | ||
| Other foci | 1 (4) | 3 (3) | 8 (7) | |||
| Unknown | 4 (18) | 50 (45) | 31 (28) | < 0.01 | 0.01 | 0.11 |
| Eradicable source | 14 (64) | 56 (51) | 58 (53) | |||
| Persistent bacteremiaa | 2/17 (12) | 15/93 (16) | 22/99 (22) | 0.18 | ||
| Metastatic infection | 4 (18) | 5 (5) | 17 (16) | 0.01 | 0.02 | 0.78 |
| Infective endocarditis or metastatic infection | 5 (23) | 5 (5) | 22 (20) | < 0.01 | < 0.01 | 0.44 |
| Illness severity | ||||||
| Pitt bacteremia score, median (IQR) | 0 (0, 2) | 1 (0, 2) | 1 (0, 2) | 0.86 | ||
| Pitt bacteremia score ≥ 4 | 3 (14) | 12 (11) | 10 (9) | 0.79 | ||
Data are expressed as numbers (%) unless otherwise indicated
Abbreviations: SLB Staphylococcus lugdunensis bacteremia, SAB Staphylococcus aureus bacteremia, SEB Staphylococcus epidermidis bacteremia, IQR Interquartile range
aThe denominator was the number of follow-up blood cultures